1. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis;Andorn;J. Clin. Psychopharmacol.,2020
2. Canadian Centre on Substance Use and Addiction, 2022. Canadian Drug Summary: Opioids. 〈https://ccsa.ca/sites/default/files/2022-11/CCSA-Canadian-Drug-Summary--Opioids-2022-en.pdf〉. (Accessed February 6 2023).
3. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence;Farrell;Int. J. Drug Policy,2022
4. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study;Gomes;Addiction,2022
5. Gomes, T., Murray, R., Kolla, G., Leece, P., Kitchen, S., Campbell, T., Besharah, J., Cahill, T., Garg, R., Iacono, A., Munro, C., Nunez, E., Robertson, L., Shearer, D., Singh, S., Toner, L., Watford, J., 2022b. Patterns of Medication and Healthcare Use among People Who Died of an Opioid-Related Toxicity during the COVID-19 Pandemic in Ontario. 〈https://odprn.ca/research/publications/opioid-related-deaths-and-healthcare-use/〉. (Accessed February 6 2023).